Private-label medical gloves for US distributors: an evidence and roles checklist
Define the exact glove, 510(k) route, manufacturer, private-label role, importer duties, QMSR controls, labelling and postmarket responsibilities before launch.
Published by NewGlove
Putting a distributor's brand on a medical glove changes more than the dispenser box. The programme must connect the exact product and intended use to the applicable 510(k), manufacturer and establishment records, device listing, label, importer structure, quality controls and postmarket responsibilities.
This guide is an education-led planning framework for established US distributors and private-label buyers. It does not state that a NewGlove product or programme is FDA cleared, listed, registered or available. It is not legal or regulatory advice. Qualified US regulatory counsel should review the exact structure and claims before commercial distribution.
Start by deciding whether the glove is a medical device
The intended use and claims determine the regulatory path. FDA identifies examination gloves, surgeon's gloves and medical gloves for handling chemotherapy agents as medical gloves. Industrial, food-service or general-purpose positioning cannot be mixed casually with medical claims.
Write the target users, procedures, settings and claims before selecting a product platform. If the programme will include both medical and non-medical SKUs, keep their files, labels, claims and distribution controls distinct.
Build a role map before requesting artwork
Supplier terms such as OEM, private label and distributor do not define FDA responsibilities by themselves. FDA's registration table distinguishes manufacturers, contract manufacturers, specification developers, relabellers or repackagers, initial importers, foreign private-label distributors and wholesale distributors. The activities actually performed determine the obligations.
Document which entity controls the device specification, manufactures and packages the glove, owns the label, submits or relies on the premarket record, imports the shipment, receives complaints and manages corrections or recalls. Contract language should match the operational reality.
- Legal manufacturer and manufacturing establishment.
- Specification developer, where applicable.
- Brand owner and label owner.
- Repackager or relabeller, if packaging or labelling changes after manufacture.
- Foreign exporter, US agent and initial importer.
- Complaint-file, medical-device-reporting, correction and recall responsibilities.
Verify the exact 510(k), listing and establishment records
FDA says medical gloves are Class I reserved devices that require a 510(k) premarket notification. A buyer should retrieve the exact clearance record and confirm the applicant, device name, product code, intended use, material, technological characteristics and any labelling conditions against the proposed private-label glove.
Then check current establishment registration and device listing separately. FDA expressly warns that it does not issue registration certificates and that registration and listing do not denote approval, clearance or authorisation. Avoid supplier certificates that imitate an FDA endorsement.
- 510(k) number, applicant, decision date, device name, product code and indications for use.
- Exact-SKU mapping for formulation, colour, dimensions, powder status, surface and packaging.
- Current manufacturer establishment registration and the correct establishment activity.
- Current device listing and proprietary-name information where applicable.
- Written regulatory rationale for the private-label presentation and any differences from the cleared device.
Treat QMSR as an operating requirement, not a certificate slogan
FDA's Quality Management System Regulation became effective on 2 February 2026. It amended 21 CFR Part 820 and incorporated ISO 13485:2016 by reference. FDA also introduced a new inspection process and states that investigators may review management review, quality-audit and supplier-audit records.
An ISO 13485 certificate can be relevant to its stated entity and scope, but it does not replace FDA requirements or exact-product evidence. The distributor programme needs controlled specifications, supplier controls, acceptance activities, nonconformance handling, complaint processes, traceability and change control aligned with the assigned roles.
Map the foreign manufacturer, US agent and initial importer
FDA states that a foreign device manufacturer must designate a US agent as part of registration. The US agent supports communication with FDA but does not automatically take responsibility for adverse-event reporting or 510(k) submissions.
FDA defines an initial importer as an importer that furthers marketing from a foreign manufacturer to the person making final delivery or sale to the ultimate user without changing the package or label. Initial importers have registration, reporting, corrections and removals, complaint-forwarding and other applicable obligations. Identify the real initial importer before the first shipment rather than adding the role after customs questions arise.
Lock the label to the regulatory file
The dispenser box, case, instructions and digital sales copy should use the same controlled product identity and claims. Do not add medical, chemotherapy, sterile, accelerator-free, latex, chemical-resistance or performance wording merely because a similar glove carries it.
Route every claim through the exact clearance, test report and formulation file. Include the correct responsible entities, lot or batch traceability, expiry and storage details, material statements, quantity, size and required cautionary wording. Control artwork versions and prohibit printer or distributor substitutions without approval.
Plan complaints, adverse events and corrections before launch
A private-label programme needs more than pre-shipment inspection. Define how complaints reach the manufacturer, how reportability is assessed, who files required reports, how trend signals are reviewed and how affected lots can be traced through distributors and customers.
Include mock-trace exercises, escalation times, retained records and decision authority for correction, removal or recall. The commercial agreement should give each party access to the information it needs to perform its assigned duties.
US private-label medical glove RFQ checklist
A useful RFQ tests regulatory and operational readiness before price. It should make unsupported shortcuts visible early and give qualified suppliers enough detail to identify the correct evidence route.
- Intended use, user, care setting, claims and target launch states or channels.
- Exact material, formulation, colour, thickness points, length, texture, cuff, sizes and pack count.
- 510(k), product code, device listing and manufacturer registration evidence for the exact product.
- Written map of manufacturer, specification developer, label owner, exporter, US agent and initial importer roles.
- QMSR readiness, supplier controls, lot acceptance, traceability and change-notification process.
- Controlled artwork, unique device identification and other applicable labelling requirements.
- Complaint, MDR, correction, removal and recall responsibilities.
- Sampling, validation, production, inspection and freight stages quoted for the actual programme, without assuming a fixed minimum or lead time.
